Viridian Therapeutics(VRDN) ZACKS·2025-05-06 13:15Core Viewpoint - Viridian Therapeutics reported a quarterly loss of $0.87 per share, which was better than the Zacks Consensus Estimate of a loss of $0.95, indicating an earnings surprise of 8.42% [1] Financial Performance - The company posted revenues of $0.07 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 55.83%, with no year-over-year revenue growth [2] - Over the last four quarters, Viridian has surpassed consensus EPS estimates two times and topped consensus revenue estimates only once [2] Stock Performance - Viridian Therapeutics shares have declined approximately 31.6% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The current Zacks Rank for the stock is 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.98 on revenues of $0.16 million, and for the current fiscal year, it is -$4.01 on revenues of $0.55 million [7] - The estimate revisions trend for Viridian is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Viridian belongs, is currently in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]